Get the Stockscreener App
0.3741
0.77%
-0.0029
Carisma Therapeutics Inc stock is traded at $0.3741, with a volume of 783.84K.
It is down -0.77% in the last 24 hours and up +34.09% over the past month.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
See More
Previous Close:
$0.377
Open:
$0.385
24h Volume:
783.84K
Relative Volume:
0.04
Market Cap:
$15.63M
Revenue:
$20.27M
Net Income/Loss:
$-63.80M
P/E Ratio:
-0.2461
EPS:
-1.52
Net Cash Flow:
$-68.35M
1W Performance:
-6.92%
1M Performance:
+34.09%
6M Performance:
-10.93%
1Y Performance:
-61.85%
1-Day Range:
$0.3604
$0.385
1-Week Range:
$0.3382
$0.44
52-Week Range:
$0.1417
$1.27
Carisma Therapeutics Inc Stock (CARM) Company Profile
Name
Carisma Therapeutics Inc
Sector
Industry
Phone
(267) 491-6422
Address
3675 MARKET STREET, PHILADELPHIA
Compare CARM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.3741 | 16.36M | 20.27M | -63.80M | -68.35M | -1.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-10-24 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-11-24 | Initiated | BTIG Research | Buy |
| Oct-03-23 | Initiated | CapitalOne | Overweight |
| Jul-06-23 | Initiated | Evercore ISI | Outperform |
| May-31-23 | Upgrade | Jefferies | Hold → Buy |
| May-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
View All
Carisma Therapeutics Inc Stock (CARM) Latest News
How to manage a losing position in Carisma Therapeutics Inc.2025 EndofYear Setup & Long Hold Capital Preservation Tips - Newser
Using AI based signals to follow Carisma Therapeutics Inc.Earnings Recap Summary & Growth Focused Stock Pick Reports - Newser
Will breakout in Carisma Therapeutics Inc. lead to full recovery2025 AllTime Highs & Daily Volume Surge Signals - Newser
Will Carisma Therapeutics Inc. price bounce be sustainableMarket Growth Summary & Community Consensus Picks - Newser
Will Carisma Therapeutics Inc. bounce back from current supportJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - Newser
Using R and stats models for Carisma Therapeutics Inc. forecastingPortfolio Update Summary & Consistent Profit Trading Strategies - Newser
Carisma Therapeutics Inc.’s volatility index tracking explained2025 Top Decliners & AI Based Buy and Sell Signals - Newser
Can Carisma Therapeutics Inc. rally from current levelsTrade Entry Summary & High Yield Equity Trading Tips - Newser
Trend analysis for Carisma Therapeutics Inc. this weekJuly 2025 Snapshot & Consistent Income Trade Recommendations - Newser
Is now a turning point for Carisma Therapeutics Inc.Analyst Upgrade & Safe Entry Zone Tips - Newser
Why Carisma Therapeutics Inc. is moving todayLong Setup & Low Risk High Win Rate Picks - Newser
Does Carisma Therapeutics Inc. qualify in momentum factor screeningMarket Growth Report & Fast Moving Stock Trade Plans - Newser
Why Carisma Therapeutics Inc. stock attracts strong analyst attentionMarket Risk Report & Real-Time Volume Trigger Notifications - Newser
Visual analytics tools that track Carisma Therapeutics Inc. performanceJuly 2025 Action & AI Enhanced Trading Alerts - Newser
How moving averages guide Carisma Therapeutics Inc. tradingLayoff News & Verified Momentum Stock Alerts - Newser
Will Carisma Therapeutics Inc. outperform the marketTrade Analysis Summary & Safe Swing Trade Setups - Newser
Will Carisma Therapeutics Inc. rebound enough to break evenJuly 2025 Fed Impact & Daily Market Momentum Tracking - Newser
Applying sector rotation models to Carisma Therapeutics Inc.2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
How to build a dashboard for Carisma Therapeutics Inc. stockPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
will carisma therapeutics inc. continue its uptrendWeekly Stock Report & Weekly Setup with High ROI Potential - Newser
What to expect from Carisma Therapeutics Inc. in the next 30 daysGDP Growth & Safe Capital Growth Tips - Newser
Applying Wyckoff theory to Carisma Therapeutics Inc. stockTrade Volume Report & Fast Momentum Stock Entry Tips - Newser
Detecting price anomalies in Carisma Therapeutics Inc. with AIVolume Spike & Safe Capital Growth Tips - Newser
carisma therapeutics inc. stock momentum explainedJuly 2025 Short Interest & AI Driven Stock Reports - Newser
Pattern recognition hints at Carisma Therapeutics Inc. upsideJuly 2025 Summary & Daily Technical Forecast Reports - Newser
How Carisma Therapeutics Inc. stock performs during market volatility2025 Major Catalysts & Community Trade Idea Sharing - Newser
Will Carisma Therapeutics Inc. stock recover after recent dropEarnings Risk Summary & Expert Curated Trade Setup Alerts - Newser
Carisma Therapeutics Inc Stock (CARM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):